|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-22
|
|
pubmed:abstractText |
Voriconazole is widely used to treat invasive aspergillosis after lung transplantation. In cystic fibrosis patients, the interindividual variability in drug disposition complicates the optimal voriconazole dosing and increases the risk of toxicity. The objective of this retrospective study was to evaluate the influence of CYP2C19 genotype on voriconazole response in lung transplant patients with cystic fibrosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1432-1041
|
|
pubmed:author |
pubmed-author:AmreinCatherineC,
pubmed-author:BeaunePhilippe HPH,
pubmed-author:BergeMaudM,
pubmed-author:BillaudEliane MEM,
pubmed-author:BoussaudVeroniqueV,
pubmed-author:ChevalierPatrickP,
pubmed-author:GuillemainRomainR,
pubmed-author:Laurent-PuigPierreP,
pubmed-author:Le BellerChristineC,
pubmed-author:Lillo-LelouetAgnesA,
pubmed-author:LoriotMarie-AnneMA,
pubmed-author:TrégouetDavid ADA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
253-60
|
|
pubmed:meshHeading |
pubmed-meshheading:21038076-Adolescent,
pubmed-meshheading:21038076-Adult,
pubmed-meshheading:21038076-Antifungal Agents,
pubmed-meshheading:21038076-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:21038076-Aspergillosis,
pubmed-meshheading:21038076-Cystic Fibrosis,
pubmed-meshheading:21038076-Dose-Response Relationship, Drug,
pubmed-meshheading:21038076-Female,
pubmed-meshheading:21038076-Genotype,
pubmed-meshheading:21038076-Humans,
pubmed-meshheading:21038076-Lung Transplantation,
pubmed-meshheading:21038076-Male,
pubmed-meshheading:21038076-Pyrimidines,
pubmed-meshheading:21038076-Retrospective Studies,
pubmed-meshheading:21038076-Triazoles,
pubmed-meshheading:21038076-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
|
|
pubmed:affiliation |
Université Paris Descartes, Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
